• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 468459 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1416978399 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1416978399 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Bearish Moving Average Cross by Auxilium Pharmaceuticals (AUXL)

Published on Thu, 03/28/2013 - 11:13
By Adrienne Chilton

Today, shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) have fallen below their 10-day MA of $17.47 on a volume of 173K shares. Swing traders may find an opportunity for a short position, as such a crossover often suggests lower prices in the near term.

There is potential upside of 38.7% for shares of Auxilium Pharmaceuticals based on a current price of $17.30 and an average consensus analyst price target of $24.00. The stock should find initial resistance at its 50-day moving average (MA) of $17.77 and further resistance at its 200-day MA of $21.20.

Over the past year, Auxilium Pharmaceuticals has traded in a range of $16.25 to $29.37 and is now at $17.30, 6% above that low. In the last five trading sessions, the 50-day moving average (MA) has fallen 0.4% while the 200-day MA has slid 0.3%.

Auxilium Pharmaceuticals Inc. develops and commercializes pharmaceutical products that target urologic and sexual health disorders. The company's marketed product ,TESTIM, is a proprietary, topical 1% testosterone gel indicated for the treatment of hypogonadism.

By Adrienne Chilton
achilton@fnno.com

Latest News from FNNO

Shares of Ventas Rise Above Previous 52-...

Ventas (NYSE:VTR) traded today at a new 52-week high of $70.11. So far today approxima ...

Shares of Validus Holdings Rise to a New...

Shares of Validus Holdings (NYSE:VR) traded at a new 52-week high today of $41.42. So ...

Watch for Continued Gains in Shares of V...

Shares of VF Corp (NYSE:VFC) traded today at $74.38, breaking its 52-week high. This n ...

Shares of Valspar Have Risen Above Previ...

Valspar (NYSE:VAL) traded at a new 52-week high today of $87.59. Approximately 849,000 ...

Visa: The Winning Streak Continues (V)...

Visa (NYSE:V) traded today at a new 52-week high of $258.00. So far today approximatel ...

Union Pacific Looks to Continue to Trade...

Union Pacific (NYSE:UNP) traded today at a new 52-week high of $123.61. This new high ...

Shares of Textron Have Risen Above Previ...

Textron (NYSE:TXT) traded at a new 52-week high today of $44.47. This new high was rea ...

Shares of Take-Two Interactive Software ...

Take-Two Interactive Software (NASDAQ:TTWO) traded today at a new 52-week high of $28.0 ...